Healing Pharma Donates Ambulance to Pune's Bhakti Siddhant Hospital Taking A Step Towards Saving Lives
New Delhi [India], August 1: In a significant step toward strengthening healthcare accessibility, Healing Pharma India Private Limited (HPIPL), one of India's fast-growing pharmaceutical companies, has donated an ambulance to Bhakti Siddhant Hospital, Pune. This life-saving gesture comes under the company's Corporate Social Responsibility (CSR) initiative, aiming to make quality critical care reachable for every life in need -- especially in underserved and emergency-prone region.
The ambulance was officially handed over in a heartwarming ceremony attended by key members of Healing Pharma's leadership team, hospital staff, local dignitaries, and community members. The vehicle is equipped with advanced life-support features designed to respond efficiently to critical emergencies -- from cardiac arrests to road accidents and maternal care transport.
"Healthcare is a basic right, not a privilege. With this ambulance, we hope to bridge the gap between critical medical need and timely intervention, especially for those who struggle with accessibility," said Mr. Sanjay Parekh and Mr. Hitesh Jain, Joint Managing Directors of Healing Pharma India Private Limited (HPIPL).
Bhakti Siddhant Hospital, which has been a pillar of affordable healthcare in Pune, will now be able to respond faster to emergencies across the region, reducing the golden-hour delay and potentially saving countless lives.
"This generous donation will go a long way in supporting our emergency response efforts. We're grateful to Healing Pharma India for recognizing the need and taking meaningful action," said Mr. Somnath Hukkeri, Dr. Shriram Baheti and Mr. Laxman Hukire Joint Managing Directors of Bhakti Siddhant Hospital.
Through such CSR interventions, Healing Pharma India continues its commitment to not just producing quality medicines but also championing real change on the ground. This initiative aligns with the company's vision of "Healthcare for All" -- beyond prescriptions and into real-world impact.
About Healing Pharma India
Healing Pharma India is a leading Pharmaceutical Company committed to manufacturing high-quality, affordable medicines on the PAN India level. With a strong ethos of ethics and empathy, the brand is actively involved in CSR efforts aimed at improving healthcare for all. For more information, visit https://www.healingpharma.in/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
6 days ago
- Business Standard
Healing Pharma Donates Ambulance to Pune's Bhakti Siddhant Hospital Taking A Step Towards Saving Lives
PNN New Delhi [India], August 1: In a significant step toward strengthening healthcare accessibility, Healing Pharma India Private Limited (HPIPL), one of India's fast-growing pharmaceutical companies, has donated an ambulance to Bhakti Siddhant Hospital, Pune. This life-saving gesture comes under the company's Corporate Social Responsibility (CSR) initiative, aiming to make quality critical care reachable for every life in need -- especially in underserved and emergency-prone region. The ambulance was officially handed over in a heartwarming ceremony attended by key members of Healing Pharma's leadership team, hospital staff, local dignitaries, and community members. The vehicle is equipped with advanced life-support features designed to respond efficiently to critical emergencies -- from cardiac arrests to road accidents and maternal care transport. "Healthcare is a basic right, not a privilege. With this ambulance, we hope to bridge the gap between critical medical need and timely intervention, especially for those who struggle with accessibility," said Mr. Sanjay Parekh and Mr. Hitesh Jain, Joint Managing Directors of Healing Pharma India Private Limited (HPIPL). Bhakti Siddhant Hospital, which has been a pillar of affordable healthcare in Pune, will now be able to respond faster to emergencies across the region, reducing the golden-hour delay and potentially saving countless lives. "This generous donation will go a long way in supporting our emergency response efforts. We're grateful to Healing Pharma India for recognizing the need and taking meaningful action," said Mr. Somnath Hukkeri, Dr. Shriram Baheti and Mr. Laxman Hukire Joint Managing Directors of Bhakti Siddhant Hospital. Through such CSR interventions, Healing Pharma India continues its commitment to not just producing quality medicines but also championing real change on the ground. This initiative aligns with the company's vision of "Healthcare for All" -- beyond prescriptions and into real-world impact. About Healing Pharma India Healing Pharma India is a leading Pharmaceutical Company committed to manufacturing high-quality, affordable medicines on the PAN India level. With a strong ethos of ethics and empathy, the brand is actively involved in CSR efforts aimed at improving healthcare for all. For more information, visit
Hindustan Times
25-07-2025
- Hindustan Times
Why access to stem cell transplants is out of reach for many thalassemia patients in India
India carries the world's most significant burden of thalassemia, with an estimated 150,000 patients and 12,000 new cases every year. While medical science continues to advance and success rates after hematopoietic stem cell transplants (HSCT) have increased globally as a potential cure for thalassemia, far too many Indian families still lack access to this life-saving treatment. The barriers are not just medical, but they are deeply rooted in systemic inequities, beginning with the first step—Human Leukocyte Antigen (HLA). Thalassemia HLAs are proteins on the surface of cells that play a crucial role in the body's immune system. They act like identification tags, allowing the immune system to distinguish between the body's cells and foreign invaders, such as bacteria or viruses. Managing thalassemia requires lifelong care that puts patient and their family into an immense financial hardship. Patients undergo regular blood transfusions and iron chelation therapy. India is the thalassemia capital of the world, with a thalassemia burden of around 150,000 patients and an incidence of approximately 12,000 every year. The recurring cost of ongoing optimal patient management varies between ₹100,000 and ₹120,000 per year. This is not affordable for most Indian families, as the estimated per capita Net National Income (NNI) of India is ₹126,000 ($ 1732). The permanent curative treatment option of HSCT is not well known in India. However, current experience worldwide indicates that more than 90% of patients now survive HSCT, and disease-free survival rates are around 80%. A significant challenge to accessing blood stem cell transplant is the associated costs, as most of the payment for HSCT is out of pocket. The Indian government is supporting ongoing patient needs through a national-level blood safety policy and the institutionalisation of state-level blood availability for patients' monthly blood transfusions and iron chelation medicines. It is also encouraging the public and private sectors to support transplant costs for poor patients as Corporate Social Responsibility (CSR) initiatives. Some states have state-level schemes to help patients with thalassemia and HSCT expenses. Thus, eligible poor patients opting for an HSCT can avail themselves of funding support from Government schemes, CSR funds, and other donations. However, these funds do not cover the costs of high-resolution HLA typing, which is the initial step in the medical assessment for an HSCT. Several global and national non-profit organisations—working towards giving patients suffering from thalassemia a second chance at life—have launched initiatives to address this gap. The initiatives include free or subsidised high-re HLA typing for families from low-income backgrounds. Such programmes are designed to enable transplant centres, NGOs, and hospitals to work in close collaboration across India. Through these initiatives, tools such as awareness drives and campaigns have also been conducted in urban and semi-urban areas to educate families about the potential cure and facilitate early intervention. These efforts have led to thousands of families receiving free HLA typing, and in numerous--instances, access to donor searches through worldwide stem cell registries when no familial match was found. We have also adopted collaborative models that not only assist Indian patients but also extend support to neighbouring countries, such as Sri Lanka, Bangladesh, and the Maldives, demonstrating the regional need for cross-border medical cooperation. Despite this advancement, large-scale systemic difficulties persist. Transplants are resource-intensive procedures that necessitate robust infrastructure, a diverse donor registry pool, donor availability, and post-transplant care. All of which demand significant public health investment. Without the wide-ranging inclusion of diagnostic tools, such as high-res HLA typing and blood stem cell transplants, in government-funded healthcare plans, treatment remains a luxury for the few rather than a right for all. The cost of a match should not be borne only by the patient or their family. It must be viewed as a shared responsibility across sectors, including government, healthcare institutions, civil society, and corporate partners alike. Only then can equitable access to curative options and care become a grounded reality for every child born with thalassemia, regardless of their socio-economic background. This article is authored by Dr Nitin Agarwal, MD, Transfusion Medicine, HOD-Donor Request Management, DKMS Foundation India.
Hans India
25-07-2025
- Hans India
ONGC to fund cancer infrastructure in three hospitals
Kakinada: Oil and Natural Gas Corporation (ONGC) has agreed to provide financial support for the installation of advanced radiation machines for cancer treatment at government hospitals in Kakinada, Guntur, and Kadapa districts. The initiative, costing Rs 48 crore, will be funded under ONGC's Corporate Social Responsibility (CSR) programme. The decision was taken following a meeting between Union Minister for Petroleum and Natural Gas Hardeep Singh Puri and a delegation comprising Dr P Chandrasekhar, Union Minister of State for Rural Development and Communications, and Rajya Sabha MP Sana Satish Babu. During the meeting held in New Delhi on Thursday, the leaders sought central assistance in strengthening the fight against cancer in Andhra Pradesh. Speaking to 'The Hans India', MP Satish Babu said that the proposal involved the procurement of three state-of-the-art radiation therapy machines, each worth approximately Rs 16 crore. Minister Puri responded positively and initiated discussions with ONGC officials, leading to the company's commitment to provide the equipment. He also said that these machines will play a crucial role in the early detection and effective radiation treatment of cancer. The equipment will soon be installed at the respective government hospitals, significantly enhancing oncology infrastructure and care in the region.
